Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Eytan M. Stein*, Courtney D. DiNardo, Daniel A. Pollyea, Amir T. Fathi, Gail J. Roboz, J. K. Altman, Richard M. Stone, Daniel J. Deangelo, Ross L. Levine, Ian W. Flinn, Hagop M. Kantarjian, Robert Collins, Manish R. Patel, Arthur E. Frankel, Anthony Stein, Mikkael A. Sekeres, Ronan T. Swords, Bruno C. Medeiros, Christophe Willekens, Paresh VyasAlessandra Tosolini, Qiang Xu, Robert D. Knight, Katharine E. Yen, Sam Agresta, Stephane De Botton, Martin S. Tallman

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

521 Scopus citations

Fingerprint Dive into the research topics of 'Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia'. Together they form a unique fingerprint.

Chemical Compounds

Medicine & Life Sciences